和元生物(688238.SH)：2025年度净亏损2.21亿元

Core Viewpoint - He Yuan Bio (688238.SH) reported a mixed performance for the fiscal year 2025, with revenue growth but continued net losses [1] Financial Performance - The company achieved operating revenue of 267.66 million yuan, representing a year-on-year increase of 7.86% [1] - The net profit attributable to the parent company was a loss of 220.72 million yuan, which is a reduction in losses by 101.10 million yuan compared to the previous year [1] - The net profit attributable to the parent company, excluding non-recurring gains and losses, was a loss of 232.02 million yuan, reflecting a decrease in losses by 103.89 million yuan year-on-year [1] Industry Context - The domestic biopharmaceutical sector is characterized by both opportunities and challenges, showcasing a complex landscape of diversified development and intense market competition [1] - The company remains focused on its core business in cell and gene therapy CRO/CDMO, leveraging national and industry development policies to strategically position itself in the regenerative medicine application field [1] Operational Strategy - During the reporting period, the company emphasized strengthening customer resource reserves, enhancing brand influence, and promoting industry development [1] - The main performance goals included improving internal capabilities, upgrading operational management, and driving cost reduction and efficiency enhancement [1] - These efforts aim to gradually improve management quality and operational efficiency, laying a solid foundation for future business development [1]